TRPC6 specifically interacts with APP to inhibit its cleavage by I 3-secretase and reduce Aβ production

Nature Communications

Volumn 6, Issue , 2015, Pages

  Wang, Junfeng ^a,b   Lu, Rui ^a,b   Yang, Jian ^c,d   Li, Hongyu ^a,b   He, Zhuohao ^a,b   Jing, Naihe ^e   Wang, Xiaomin ^c   Wang, Yizheng ^a  

^a Shenzhen Fundamental Research Institutions   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; CALCIUM CHANNEL; GAMMA SECRETASE; NERVE CELL ADHESION MOLECULE; NOTCH RECEPTOR; PRESENILIN 1; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; UVOMORULIN; PROTEIN BINDING; SECRETASE; TRANSIENT RECEPTOR POTENTIAL CHANNEL C; TRPC6 PROTEIN, HUMAN;

ENZYME ACTIVITY; GENE EXPRESSION; GENETICALLY MODIFIED ORGANISM; NERVOUS SYSTEM DISORDER; PHYSIOLOGICAL RESPONSE; PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN CELL; CELL FUNCTION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENHANCER REGION; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; IMMUNOPRECIPITATION; IN VITRO STUDY; MALE; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; POINT MUTATION; PRECIPITATION; PROTEIN CLEAVAGE; PROTEIN SYNTHESIS INHIBITION; RAT; ALZHEIMER DISEASE; ANIMAL; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; FEMALE; HUMANS; MALE; MICE; MICE, TRANSGENIC; PRESENILIN-1; PROTEIN BINDING; TRPC CATION CHANNELS;

EID: 84947604855     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9876     Document Type: Article

References (49)

1. Hardy, J. &Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356 (2002).
2. De Strooper, B., Vassar, R. &Golde, T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat. Rev. Neurol. 6, 99-107 (2010).
3. Haapasalo, A. &Kovacs, D. M. The many substrates of presenilin/gammasecretase. J. Alzheimers Dis. 25, 3-28.
4. Xia, W. &Wolfe, M. S. Intramembrane proteolysis by presenilin and presenilin-like proteases. J. Cell. Sci. 116, 2839-2844 (2003).
5. Doody, R. S. et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N. Engl. J. Med. 369, 341-350 (2013).
6. Chavez-Gutierrez, L. et al. The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease. EMBO J. 31, 2261-2274 (2012).
7. Selkoe, D. J. Resolving controversies on the path to Alzheimer's therapeutics. Nat. Med. 17, 1060-1065 (2011).
8. Montell, C., Birnbaumer, L. &Flockerzi, V. The TRP channels, a remarkably functional family. Cell 108, 595-598 (2002).
9. Clapham, D. E. TRP channels as cellular sensors. Nature 426, 517-524 (2003).
10. Tai, Y., Feng, S., Du, W. &Wang, Y. Functional roles of TRPC channels in the developing brain. Pflugers Arch. 458, 283-289 (2009).
11. Ding, X. et al. Essential role of TRPC6 channels in G2/M phase transition and development of human glioma. J. Natl Cancer Inst. 102, 1052-1068 (2010).
12. Du, W. et al. Inhibition of TRPC6 degradation suppresses ischemic brain damage in rats. J. Clin. Invest. 120, 3480-3492 (2010).
13. Lessard, C. B., Lussier, M. P., Cayouette, S., Bourque, G. &Boulay, G. The overexpression of presenilin2 and Alzheimer's-disease-linked presenilin2 variants influences TRPC6-enhanced Ca2 entry into HEK293 cells. Cell. Signal. 17, 437-445 (2005).
14. Selkoe, D. J. Alzheimer's disease is a synaptic failure. Science 298, 789-791 (2002).
15. Terry, R. D. et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572-580 (1991).
16. Gomez-Isla, T. et al. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J. Neurosci. 16, 4491-4500 (1996).
17. Jia, Y., Zhou, J., Tai, Y. &Wang, Y. TRPC channels promote cerebellar granule neuron survival. Nat. Neurosci. 10, 559-567 (2007).
18. Griesi-Oliveira, K. et al. Modeling non-syndromic autism and the impact of TRPC6 disruption in human neurons. Mol. Psychiatry 20, 1350-1365 (2015).
19. Zhou, J. et al. Critical role of TRPC6 channels in the formation of excitatory synapses. Nat. Neurosci. 11, 741-743 (2008).
20. Kim, J. H., Choi, S., Jung, J. E., Roh, E. J. &Kim, H. J. Capacitative Ca2 entry is involved in regulating soluble amyloid precursor protein (sAPPalpha) release mediated by muscarinic acetylcholine receptor activation in neuroblastoma SH-SY5Y cells. J. Neurochem. 97, 245-254 (2006).
21. Dreses-Werringloer, U. et al. A polymorphism in CALHM1 influences Ca2 homeostasis, Abeta levels, and Alzheimer's disease risk. Cell 133, 1149-1161 (2008).
22. Hoey, S. E., Williams, R. J. &Perkinton, M. S. Synaptic NMDA receptor activation stimulates alpha-secretase amyloid precursor protein processing and inhibits amyloid-beta production. J. Neurosci. 29, 4442-4460 (2009).
23. Hofmann, T. et al. Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature 397, 259-263 (1999).
24. Merritt, J. E. et al. SK&F 96365, a novel inhibitor of receptor-mediated calcium entry. Biochem. J. 271, 515-522 (1990)
25. Hofmann, T., Schaefer, M., Schultz, G. &Gudermann, T. Subunit composition of mammalian transient receptor potential channels in living cells. Proc. Natl Acad. Sci. USA 99, 7461-7466 (2002).
26. Bates, K. A. et al. Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol. Psychiatry 14, 469-486 (2009).
27. Tanzi, R. E., Moir, R. D. &Wagner, S. L. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 43, 605-608 (2004).
28. Pardossi-Piquard, R. &Checler, F. The physiology of the beta-amyloid precursor protein intracellular domain AICD. J. Neurochem. 120 (Suppl 1), 109-124 (2012).
29. Schroeter, E. H., Kisslinger, J. A. &Kopan, R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 393, 382-386 (1998).
30. Suzuki, T. &Nakaya, T. Regulation of amyloid beta-protein precursor by phosphorylation and protein interactions. J. Biol. Chem. 283, 29633-29637 (2008).
31. Leuner, K. et al. Hyperforin a key constituent of St John's wort specifically activates TRPC6 channels. FASEB J. 21, 4101-4111 (2007).
32. Jankowsky, J. L. et al. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 17, 157-165 (2001).
33. Youmans, K. L. et al. Intraneuronal Abeta detection in 5xFAD mice by a new Abeta-specific antibody. Mol. Neurodegener. 7, 8 (2012).
34. Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P. &Kivipelto, M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 9, 702-716 (2010).
35. Thathiah, A. et al. The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons. Science 323, 946-951 (2009).
36. Serneels, L. et al. gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science 324, 639-642 (2009).
37. Phiel, C. J., Wilson, C. A., Lee, V. M. &Klein, P. S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423, 435-439 (2003).
38. Flajolet, M. et al. Regulation of Alzheimer's disease amyloid-beta formation by casein kinase I. Proc. Natl Acad. Sci. USA 104, 4159-4164 (2007).
39. Teng, L., Zhao, J., Wang, F., Ma, L. &Pei, G. A GPCR/secretase complex regulates beta-and gamma-secretase specificity for Abeta production and contributes to AD pathogenesis. Cell Res. 20, 138-153 (2010).
40. Chen, F. et al. TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity. Nature 440, 1208-1212 (2006).
41. Gong, P. et al. Transgenic neuronal overexpression reveals that stringently regulated p23 expression is critical for coordinated movement in mice. Mol. Neurodegener. 6, 87 (2011).
42. He, G. et al. Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 467, 95-98 (2010).
43. Kukar, T. L. et al. Substrate-targeting gamma-secretase modulators. Nature 453, 925-929 (2008).
44. Gomez-Ospina, N., Tsuruta, F., Barreto-Chang, O., Hu, L. &Dolmetsch, R. The C terminus of the L-type voltage-gated calcium channel Ca(V)1.2 encodes a transcription factor. Cell 127, 591-606 (2006).
45. Runnels, L. W. TRPM6 and TRPM7: a Mul-TRP-PLIK-cation of channel functions. Curr. Pharm. Biotechnol. 12, 42-53 (2011).
46. Heo, D. K. et al. Opposite regulatory effects of TRPC1 and TRPC5 on neurite outgrowth in PC12 cells. Cell. Signal. 24, 899-906 (2012).
47. Verghese, P. B. et al. ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Proc. Natl Acad. Sci. USA 110, E1807-E1816 (2013).
48. He, Z. et al. TRPC5 channel is the mediator of neurotrophin-3 in regulating dendritic growth via CaMKIIalpha in rat hippocampal neurons. J. Neurosci. 32, 9383-9395 (2012).
49. Lee, M. S. et al. APP processing is regulated by cytoplasmic phosphorylation. J. Cell Biol. 163, 83-95 (2003)